2
Clinical Trials associated with Polysaccharide Superparamagnetic Iron OxideOpen-label, Single-dose Study of Polysaccharide Superparamagnetic Iron Oxide Injection for Contrast-enhanced Cardiovascular Magnetic Resonance Imaging in Patients With Type 2 Diabetes and Chronic Kidney Disease.
This is an open-label, single-center, single-dose study aims to evaluate the effect and safety of polymeric superparamagnetic iron oxide in cardiovascular magnetic resonance imaging for diabetic patients with concomitant chronic kidney disease.
A Single-center, Randomized, Open-label, Single-dose Study of Polysaccharide Superparamagnetic Iron Oxide Injection in Healthy Subjects to Evaluate Magnetic Resonance Imaging in Multiple Dose Groups
This is a contrast-enhanced magnetic resonance imaging (MRI) study conducted on a single-administration of polyglucose superparamagnetic iron oxide injection. Two dose groups are set up in this study, 2.5 mg/kg and 3 mg/kg, and two subjects in each group received the test drug for safety evaluation.
100 Clinical Results associated with Polysaccharide Superparamagnetic Iron Oxide
100 Translational Medicine associated with Polysaccharide Superparamagnetic Iron Oxide
100 Patents (Medical) associated with Polysaccharide Superparamagnetic Iron Oxide
100 Deals associated with Polysaccharide Superparamagnetic Iron Oxide